Table 1 Characteristics and of patients and healthy control subjects
From: IgG Fc galactosylation predicts response to methotrexate in early rheumatoid arthritis
|  | Healthy control subjects (n = 11) | Early RA | ||||
|---|---|---|---|---|---|---|
All patients (n = 59) | GR (n = 19) | MR (n = 20) | NR (n = 20) | p Valuea | ||
Age, years | 54 (45–57) | 53 (45–62) | 49 (41–63) | 49 (41–56) | 55 (49–65) | 0.03 |
Female sex | 73% | 72% | 68% | 65% | 80% | 0.28 |
Current smoking | 10% | 34% | 31% | 30% | 30% | 0.52 |
ACPA- and/or RF-positive | – | 75% | 74% | 75% | 75% | 0.96 |
DAS28-ESR | – | 5.7 (5.0–6.2) | 5.2 (5.0–6.0) | 6.0 (5.4–6.4) | 5.2 (4.7–6.4) | 0.40 |
HAQ | – | 1.3 (0.9–1.6) | 1.1 (0.8–1.4) | 1.4 (1.0–1.9) | 1.3 (0.9–1.6) | 0.66 |
DAS28-ESR follow-up | – | 4.5 (2.6–5.1) | 2.2 (1.7–2.6) | 4.4 (4.0–4.9) | 5.4 (4.9–5.8) | <0.0001 |
MTX duration, weeks | – | 14 (13–15) | 14 (13–15) | 14 (13–15) | 14 (14–15) | 0.50 |
Prednisolone | – | 25% | 31% | 30% | 15% | 0.19 |